<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00569023</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-06-4496-YR-CTIL</org_study_id>
    <nct_id>NCT00569023</nct_id>
  </id_info>
  <brief_title>Treatment of Congenital Stationary Night Blindness With an Alga Containing High Dose of Beta Carotene</brief_title>
  <official_title>Treatment of Congenital Stationary Night Blindness With an Alga Containing High Dose of Beta Carotene</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the effect of oral administration of the alga Dunaliella bardawil containing&#xD;
      approximately 50% all-trans beta-carotene and 50% 9-cis beta-carotene isomers on visual&#xD;
      functions patients with Congenital Stationary Night Blindness {Fundus albipunctatus).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Electroretinogram responses</measure>
    <time_frame>Three months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>Three Months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Night Blindness</condition>
  <arm_group>
    <arm_group_label>A,1,I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>alga Dunaliella bardawil</intervention_name>
    <description>Each patients will be treated with four capsules daily of Dunaliella bardawil for 90 days.&#xD;
Alga Dunaliella bardawil containing 15 mg approximately 50% all-trans beta-carotene and 50% 9-cis beta-carotene isomers</description>
    <arm_group_label>A,1,I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent to participate in the study.&#xD;
&#xD;
          -  Men or women aged 18 years or older&#xD;
&#xD;
          -  Diagnosed with Fundus albipunctatus&#xD;
&#xD;
               1. Isolated rod response markedly reduced (less than 20% of normal)after 20 minutes&#xD;
                  dark adaptation and improved by 50% after 2 hours&#xD;
&#xD;
               2. Negative maximal response (a wave to b wave ratio less than 2)&#xD;
&#xD;
               3. Retinal midperipheral white dots (More than 3000 dots)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current smokers.&#xD;
&#xD;
          -  Current use of Vitamin A/ beta carotene supplements.&#xD;
&#xD;
          -  Active arterial disease within 3 months of study entry such as unstable angina,&#xD;
             myocardial infarction, transient ischemic attack (TIA), stroke, and coronary artery&#xD;
             bypass graft (CABG) surgery.&#xD;
&#xD;
          -  History of malignancy, except basal or squamous cell skin carcinoma.&#xD;
&#xD;
          -  Pregnant women, women who are breast feeding, and women of childbearing potential who&#xD;
             are not using chemical or mechanical contraception.&#xD;
&#xD;
          -  Uncontrolled hypertension defined as either resting diastolic blood pressure of&#xD;
             &gt;95mmHg (taken from the mean of 3 readings) or resting systolic blood Pressure of &gt;&#xD;
             180 mmHg.&#xD;
&#xD;
          -  History of alcohol abuse or drug abuse, or both.&#xD;
&#xD;
          -  Active liver disease or hepatic dysfunction as defined by elevations of 2.0 times the&#xD;
             ULN in any of the following liver function tests: ALT, AST or bilirubin.&#xD;
&#xD;
          -  Serum CPK &gt; 2.0 times ULN in visit 0&#xD;
&#xD;
          -  TSH above the normal range.&#xD;
&#xD;
          -  Newly diagnosed diabetes within 3 months.&#xD;
&#xD;
          -  Patient plans to engage in vigorous exercise or an aggressive diet regimen.&#xD;
&#xD;
          -  Uncontrolled endocrine or metabolic disease.&#xD;
&#xD;
          -  Participation in another investigational drug study within 4 weeks of entry into this&#xD;
             study.&#xD;
&#xD;
          -  Serious or unstable medical or psychological condition that, in the opinion of the&#xD;
             investigator, would compromise the subject's safety or successful participation in the&#xD;
             study.&#xD;
&#xD;
          -  Serum creatinine &gt; 2.0 mg/dl before the treatment phase, +3 proteinuria in urine&#xD;
             dipstick, or a history of renal transplantation before the treatment period.&#xD;
&#xD;
          -  Subject whose hormone replacement therapy (HRT) or oral contraceptive therapy (OCT)&#xD;
             was initiated within the 3 month prior to enrollment.&#xD;
&#xD;
          -  Forbidden medications: the combination of PPAR alpha agonists-fibric acid derivatives,&#xD;
             PPAR gamma agonists.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ygal Rotenstreich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>December 5, 2007</study_first_submitted>
  <study_first_submitted_qc>December 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2007</study_first_posted>
  <last_update_submitted>June 26, 2012</last_update_submitted>
  <last_update_submitted_qc>June 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Ygal Rotenstreich</investigator_full_name>
    <investigator_title>Opthalmologist</investigator_title>
  </responsible_party>
  <keyword>Beta Carotene</keyword>
  <keyword>visual functions</keyword>
  <keyword>Fundus albipunctatus</keyword>
  <keyword>Night Blindness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blindness</mesh_term>
    <mesh_term>Night Blindness</mesh_term>
    <mesh_term>Vitamin A Deficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

